1. 017 Anti-Fibrotic Properties of RhoA Kinase-Inhibition in a Cell Culture Model of Peyronie's Disease. (1st July 2018) Authors: Milenkovic, U.; Ilg, M.M.; van Renterghem, K.; De Ridder, D.; Albersen, M. Journal: Journal of sexual medicine Issue: Volume 15(2018)Supplement 3 Page Start: S130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 022 Vardenafil and Tamoxifen Synergise in a Rat Model of Peyronie's Disease. (1st July 2018) Authors: Ilg, M.M.; Milenkovic, U.; Muneer, A.; Albersen, M.; Cellek, S.; Ralph, D.J. Journal: Journal of sexual medicine Issue: Volume 15(2018)Supplement 3 Page Start: S132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 277 Interplay Between TNFa and TGF-B1 in a Cell Culture Model of Peyronie's Disease. (1st July 2018) Authors: Milenkovic, U.; Ilg, M.M.; van Renterghem, K.; De Ridder, D.; Albersen, M. Journal: Journal of sexual medicine Issue: Volume 15(2018)Supplement 3 Page Start: S234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PS-3-2 High-Throughput Phenotypic Screening Campaign of 1, 954 FDA-Approved Drugs Reveals 41 Hits With Anti-Myofibroblast Activity in an in Vitro Model of Peyronie's Disease. (1st June 2020) Authors: Ilg, M.M.; Lapthorn, A.R.; Muneer, A.; Christopher, N.; Cellek, S.; Ralph, D.J. Journal: Journal of sexual medicine Issue: Volume 17(2020)Supplement 2 Page Start: S129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗